Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director · CFO, President | May 22, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 500,000 |
Reported balance
After 2026-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 500,000 · Balance 500,000 F1: The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001493152-26-026428 · ownership.xml · derivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-05-22 F1 · derivative.exercise_date: The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:47 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 770 | $6.58 | $5,066.60 |
DisclosureSEC source: 0001493152-25-027107 · ownership.xml · nonDerivative · entry 2 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,429 Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 23:47 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | OtherWarrants (right to purchase) · Derivative | 60,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001493152-25-027107 · ownership.xml · derivative · entry 5 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common stock · 60,000 shares Expires 2031-04-02 F1 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein. F3 · ownership.nature: The warrants were held by Alwaysraise LLC. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 23:47 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | OtherWarrants (right to purchase) · Derivative | 96,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001493152-25-027107 · ownership.xml · derivative · entry 4 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common stock · 96,000 shares Expires 2031-03-18 F1 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein. F3 · ownership.nature: The warrants were held by Alwaysraise LLC. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 23:47 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | OtherCommon Stock | 156,000 | $0.80 | $124,800.00 |
DisclosureSEC source: 0001493152-25-027107 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 426,844 F1 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 21:20 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 2,600 | $1.97 | $5,122.00 |
DisclosureSEC source: 0001493152-25-013918 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,659 Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:57 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001641172-25-016114 · ownership.xml · derivative · entry 4 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2035-06-20 F3 · derivative.exercise_date: The Stock Option will vest in forty-eight (48) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 13:35 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 2,225 | $2.28 | $5,070.78 |
DisclosureSEC source: 0001641172-25-015755 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,059 F1 · price: Volume-weighted average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2024 Filed Jun 21, 2024 21:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-24-024826 · ownership.xml · derivative · entry 4 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2034-06-11 F3 · derivative.exercise_date: The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 13:00 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 2,500 | $2.12 | $5,298.00 |
DisclosureSEC source: 0001493152-24-023288 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,834 Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 13:00 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 3,300 | $1.81 | $5,972.67 |
DisclosureSEC source: 0001493152-24-022654 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,334 Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 24,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-020776 · ownership.xml · nonDerivative · entry 3 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 24,141 F1 · price: Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. F3 · ownership.nature: Gabriel Morris is the Managing Partner of Alwaysraise Ventures I Investments, LLC ("Alwaysraise Ventures"), the general partner of Alwaysraise Ventures I, LP. ("AVILP") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by AVILP, except to the extent of his pecuniary interest therein. Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 24,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-020776 · ownership.xml · nonDerivative · entry 2 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 270,844 F1 · price: Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. F2 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein. Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 194,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-020776 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,034 F1 · price: Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. Read SEC document |
| May 14, 2024 Filed May 15, 2024 01:29 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 4,500 | $2.23 | $10,041.75 |
DisclosureSEC source: 0001493152-24-019368 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,816 Read SEC document |
| August 14, 2023 Filed Nov 10, 2023 00:57 UTC Amendment | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 293,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001493152-23-040177 · ownership.xml · derivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,000 Underlying: Common Stock · 293,000 shares Expires 2033-08-14 F1 · derivative.exercise_date: Options vest monthly over 48 months from the date of grant. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 20:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 193,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001493152-23-028477 · ownership.xml · derivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,000 Underlying: Common Stock · 193,000 shares Expires 2033-08-11 F1 · derivative.exercise_date: Options vest monthly over 48 months from the date of grant. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 22:31 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 5,200 | $0.94 | $4,888.00 |
DisclosureSEC source: 0001493152-22-032555 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,316 Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 10:02 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001493152-22-019497 · ownership.xml · derivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,500 Underlying: Common Stock · 250,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: Options vest monthly in equal amounts over 48 months. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $0.85 | $100,000.00 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · derivative · entry 7 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common stock · 123,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 2, 2021, the Registrant issued Alwaysraise a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F4 · derivative.expiration_date: On April 2, 2021, the Registrant issued Alwaysraise a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F3 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $0.85 | $100,000.00 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · derivative · entry 6 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common stock · 123,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On March 18, 2021, the Registrant issued Alwaysraise LLC a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F2 · derivative.expiration_date: On March 18, 2021, the Registrant issued Alwaysraise LLC a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F3 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $0.85 | $60,000.00 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · derivative · entry 5 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 74,116 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On March 18, 2021, the Registrant issued the Reporting Person a note in the amount of $60,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. F1 · derivative.expiration_date: On March 18, 2021, the Registrant issued the Reporting Person a note in the amount of $60,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 2,000 | $5.00 | $10,000.00 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · nonDerivative · entry 4 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,116 Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionCommon Stock | 123,176 | $0.85 | $104,699.60 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · nonDerivative · entry 3 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 246,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionCommon Stock | 123,527 | $0.85 | $104,997.95 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · nonDerivative · entry 2 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 123,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 21:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | ConversionCommon Stock | 74,116 | $0.85 | $62,998.60 |
DisclosureSEC source: 0001493152-21-032035 · ownership.xml · nonDerivative · entry 1 Morris Gabriel S · CIK 0001889967 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.